



Date: 06 February 2020

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Lapsing of Unlisted Options

Sydney, 06 February 2020: Noxopharm (ASX: NOX) advises that the following unlisted options have lapsed on 6 February 2020:

ASX Unquoted Securities	Number of Options	Exercise Price
NOXAT	22,091	\$1.08
NOXAT	18,750	\$0.62

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

www.noxopharm.com

Ends

.....
Approval. This announcement has been approved and authorised for release by Dr Graham Kelly, Noxopharm CEO, by authority of the Noxopharm Board.

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@noxopharm.com

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@atomicgroup.com.au



Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.